{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:44:20Z","timestamp":1781311460974,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"29-30","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.vaccine.2006.04.042","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T17:09:17Z","timestamp":1147194557000},"page":"5690-5699","source":"Crossref","is-referenced-by-count":51,"title":["Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program"],"prefix":"10.1016","volume":"24","author":[{"given":"Torbj\u00f8rn","family":"Wisl\u00f8ff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore G.","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne A. Riise","family":"Bergsaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8istein","family":"L\u00f8voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren Kristine","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar S\u00f8nb\u00f8","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1A","key":"10.1016\/j.vaccine.2006.04.042_bib1","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1016\/S0002-9343(99)00098-4","article-title":"Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978\u20131997","volume":"107","author":"Mufson","year":"1999","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.042_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.275.3.194","article-title":"Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group","volume":"275","author":"Plouffe","year":"1996","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.vaccine.2006.04.042_bib3","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/JCM.33.10.2759-2762.1995","article-title":"Six newly recognized types of Streptococcus pneumoniae","volume":"33","author":"Henrichsen","year":"1995","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2006.04.042_bib4","series-title":"Increased use of pneumococcal vaccine in Norway","author":"H\u00f8iby","year":"1996"},{"issue":"23","key":"10.1016\/j.vaccine.2006.04.042_bib5","first-page":"2732","article-title":"All persons without spleen should be given pneumococcal vaccine","volume":"114","author":"Aaberge","year":"1994","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.042_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2006.04.042_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.042_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00006454-200203000-00003","article-title":"Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants","volume":"21","author":"Shinefield","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2006.04.042_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00006454-200301000-00006","article-title":"Impact of the pneumococcal conjugate vaccine on otitis media","volume":"22","author":"Fireman","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9381","key":"10.1016\/j.vaccine.2006.04.042_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(03)14022-6","article-title":"Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial","volume":"362","author":"O\u2019Brien","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2006.04.042_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"issue":"9376","key":"10.1016\/j.vaccine.2006.04.042_bib12","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/S0140-6736(03)13772-5","article-title":"Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study","volume":"361","author":"Veenhoven","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2006.04.042_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00019053-200321080-00005","article-title":"Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany","volume":"21","author":"Claes","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2006.04.042_bib14","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1016\/S0264-410X(03)00361-X","article-title":"Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada","volume":"21","author":"De Wals","year":"2003","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2006.04.042_bib15","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/S0149-2918(03)80322-3","article-title":"Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands","volume":"25","author":"Bos","year":"2003","journal-title":"Clin Ther"},{"issue":"1920","key":"10.1016\/j.vaccine.2006.04.042_bib16","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/S0264-410X(03)00031-8","article-title":"The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine","volume":"21","author":"McIntosh","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2006.04.042_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1524-4733.2004.71263.x","article-title":"A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain","volume":"7","author":"Asensi","year":"2004","journal-title":"Value Health"},{"issue":"18","key":"10.1016\/j.vaccine.2006.04.042_bib18","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1001\/jama.291.18.2197","article-title":"Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections","volume":"291","author":"Flannery","year":"2004","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.vaccine.2006.04.042_bib19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2006.04.042_bib20","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"issue":"36","key":"10.1016\/j.vaccine.2006.04.042_bib21","first-page":"893","article-title":"Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease\u2014United States, 1998\u20132003","volume":"54","year":"2005","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2006.04.042_bib22","first-page":"108","article-title":"Notice to readers\u2014limited supply of pneumococcal conjugate vaccine: suspension of recommendation for fourth dose","volume":"53","author":"CDC","year":"2004","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2006.04.042_bib23","first-page":"177","article-title":"Notice to readers\u2014updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose","volume":"53","author":"CDC","year":"2004","journal-title":"MMWR"},{"issue":"2 Pt 1","key":"10.1016\/j.vaccine.2006.04.042_bib24","first-page":"362","article-title":"Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis","volume":"106","author":"American Academy of Pediatrics","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2006.04.042_bib25","unstructured":"K\u00e4yhty H, \u00c5hman H, Eriksson K, S\u00f6rberg M, Nilsson L. Pneumococcal conjugate vaccine (PncCRM) is immunogenic when administres at 3, 5, and 12 months of age. ESPID; 2003 [abstract]."},{"issue":"2","key":"10.1016\/j.vaccine.2006.04.042_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/01.inf.0000151022.92222.be","article-title":"Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age","volume":"24","author":"K\u00e4yhty","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"10.1016\/j.vaccine.2006.04.042_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.vaccine.2004.09.029","article-title":"Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants","volume":"23","author":"Esposito","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2006.04.042_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0196-0709(86)80034-5","article-title":"Epidemiology of acute suppurative otitis media","volume":"7","author":"Stangerup","year":"1986","journal-title":"Am J Otolaryngol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.042_bib29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-5876(01)00626-7","article-title":"Acute mastoiditis in a Norwegian population: a 20 year retrospective study","volume":"62","author":"Vassbotn","year":"2002","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.04.042_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/000348940311200408","article-title":"Is secretory otitis media a single disease entity?","volume":"112","author":"Sade","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.04.042_bib31","first-page":"389","article-title":"Transtympanic ventilator tubes in the treatment of seromucous otitis. Indications and results","volume":"113","author":"Moller","year":"1992","journal-title":"Rev Laryngol Otol Rhinol (Bord.)"},{"key":"10.1016\/j.vaccine.2006.04.042_bib32","series-title":"Evidence-based otitis media","year":"2003"},{"issue":"4","key":"10.1016\/j.vaccine.2006.04.042_bib33","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/archotol.1987.01860040042014","article-title":"Dynamics of eardrum changes following secretory otitis. A prospective study","volume":"113","author":"Tos","year":"1987","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.vaccine.2006.04.042_bib34","first-page":"87","article-title":"Sensorineural hearing loss in acute and chronic middle ear diseases","volume":"457","author":"Tos","year":"1989","journal-title":"Acta Otolaryngol Suppl"},{"issue":"2","key":"10.1016\/j.vaccine.2006.04.042_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S0950268803001511","article-title":"Systemic pneumococcal disease in Norway 1995\u20132001: capsular serotypes and antimicrobial resistance","volume":"132","author":"Pedersen","year":"2004","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2006.04.042_bib36","series-title":"Activity based financing, DRG-price list","author":"Anonymous","year":"2004"},{"key":"10.1016\/j.vaccine.2006.04.042_bib37","unstructured":"Harvard Centre for Risk Analysis. http:\/\/www.hsph.harvard.edu\/cearegistry\/. 2005."},{"key":"10.1016\/j.vaccine.2006.04.042_bib38","unstructured":"Norwegian Ministry of Finance. Guidelines for social economics analyses, Norway; 2005."},{"issue":"6","key":"10.1016\/j.vaccine.2006.04.042_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.inf.0000069760.65826.f2","article-title":"Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings","volume":"22","author":"Givon-Lavi","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2006.04.042_bib40","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0264-410X(02)00807-1","article-title":"The potential indirect effect of conjugate pneumococcal vaccines","volume":"21","author":"O\u2019Brien","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2006.04.042_bib41","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/00006454-200112000-00002","article-title":"Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine","volume":"20","author":"Black","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"10.1016\/j.vaccine.2006.04.042_bib42","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","article-title":"Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae","volume":"354","author":"Kyaw","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2006.04.042_bib43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.284.4.440","article-title":"Cost-effectiveness of pneumococcal vaccine","volume":"284","author":"Lieu","year":"2000","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.vaccine.2006.04.042_bib44","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1016\/S0264-410X(03)00193-2","article-title":"Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland","volume":"21","author":"Ess","year":"2003","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.042_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1086\/345833","article-title":"A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada","volume":"36","author":"Lebel","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2006.04.042_bib46","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.vaccine.2005.01.018","article-title":"Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)","volume":"23","author":"Navas","year":"2005","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2006.04.042_bib47","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.vaccine.2004.08.051","article-title":"Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)","volume":"23","author":"McIntosh","year":"2005","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2006.04.042_bib48","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1016\/j.vaccine.2005.04.033","article-title":"Cost-effectiveness of universal pneumococcal vaccination for infants in Italy","volume":"23","author":"Marchetti","year":"2005","journal-title":"Vaccine"},{"issue":"31\u201332","key":"10.1016\/j.vaccine.2006.04.042_bib49","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2006.04.042_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00365540500321512","article-title":"Economic evaluation of pneumococcal conjugate vaccination in Finland","volume":"37","author":"Salo","year":"2005","journal-title":"Scand J Infect Dis"},{"issue":"9260","key":"10.1016\/j.vaccine.2006.04.042_bib51","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(00)04222-7","article-title":"Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children","volume":"357","author":"Hausdorff","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.04.042_bib52","unstructured":"OECD Health Data 2005. http:\/\/www.oecd.org\/document\/30\/0, 2e231111300h; 2006."},{"key":"10.1016\/j.vaccine.2006.04.042_bib53","unstructured":"The World Bank. http:\/\/www.who.int\/bulletin\/news\/2000\/vol.78no.2\/cost-effectivevaccines.htm; 2005."},{"key":"10.1016\/j.vaccine.2006.04.042_bib54","article-title":"Hvor mye b\u00f8r samfunnet v\u00e6re villig til \u00e5 betale for helseforbedringer?","author":"Kristiansen","year":"2003"},{"issue":"7324","key":"10.1016\/j.vaccine.2006.04.042_bib55","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/bmj.323.7324.1300","article-title":"NICE: faster access to modern treatments? Analysis of guidance on health technologies","volume":"323","author":"Raftery","year":"2001","journal-title":"BMJ"},{"issue":"7459","key":"10.1016\/j.vaccine.2006.04.042_bib56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.329.7459.224","article-title":"National Institute for Clinical Excellence and its value judgments","volume":"329","author":"Rawlins","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.vaccine.2006.04.042_bib57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06005056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06005056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T01:28:02Z","timestamp":1627349282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06005056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":57,"journal-issue":{"issue":"29-30","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0264410X06005056"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.04.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}